Holen Sie sich die Stockscreener-App
301.66
1.99%
-6.12
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$307.78
Offen:
$306.13
24-Stunden-Volumen:
238.60K
Relative Volume:
0.64
Marktkapitalisierung:
$7.12B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-518.67M
KGV:
-12.01
EPS:
-25.12
Netto-Cashflow:
$-438.32M
1W Leistung:
-1.85%
1M Leistung:
-11.91%
6M Leistung:
+43.33%
1J Leistung:
+32.11%
1-Tages-Spanne:
$298.36
$306.81
1-Wochen-Bereich:
$292.49
$330.64
52-Wochen-Spanne:
$189.00
$377.46
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Vergleichen Sie MDGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
301.66 | 7.12B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Leadership Changes at Madrigal Pharmaceuticals Mark New Phase of Growth - MSN
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals to Release Q1 2025 Financial Results on May 1, 2025 - Nasdaq
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 - GlobeNewswire
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 - GlobeNewswire Inc.
Madrigal Pharmaceuticals announces executive transition By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals announces executive transition - Investing.com Australia
Madrigal Pharmaceuticals Announces Leadership Transition - TipRanks
(MDGL) Technical Data - news.stocktradersdaily.com
Madrigal founder Rebecca Taub to step back; firm hires successor from Novartis - The Business Journals
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer - The Manila Times
Madrigal Pharmaceuticals Announces Company Founder Rebecca - GlobeNewswire
Madrigal Pharmaceuticals Announces Changes to Board of Directors - MSN
Madrigal Pharmaceuticals to Announce Q4 and Full-Year 2024 Results with Live Webcast - MSN
Trend Tracker for (MDGL) - news.stocktradersdaily.com
Cytokinetics, Madrigal, and BridgeBio Emerge as Potential Pharma Takeover Targets - GuruFocus
Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March? - Yahoo
Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Analysts Expect Breakeven For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Before Long - simplywall.st
(MDGL) On The My Stocks Page - Stock Traders Daily
EU health regulator clears use of AI tool in fatty liver disease trials - Reuters
Madrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
Madrigal Pharmaceuticals SVP and CFO sells stock for $83,344 - Investing.com India
Madrigal Pharmaceuticals’ SWOT analysis: Rezdiffra success drives stock potential By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals’ SWOT analysis: Rezdiffra success drives stock potential - Investing.com India
Madrigal Pharmaceuticals SVP and CFO sells stock for $83,344 By Investing.com - Investing.com Australia
Victory Capital Management Inc. Has $21.80 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Bank of New York Mellon Corp Lowers Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Madrigal Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia
How the (MDGL) price action is used to our Advantage - Stock Traders Daily
Madrigal Pharmaceuticals Expands Board with New Appointment - TipRanks
Madrigal appoints Jacqualyn Fouse to its board -March 11, 2025 at 09:36 am EDT - Marketscreener.com
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. To Board - citybiz
Madrigal Pharmaceuticals appoints new board member - Investing.com India
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors - The Manila Times
Why Madrigal Pharmaceuticals (MDGL) Stock is Rising Today - GuruFocus.com
Robert E. Waltermire Sells 14,113 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock - Defense World
Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, - GuruFocus.com
Madrigal Pharmaceuticals Exec Cashes Out in Multi-Million Dollar Stock Sale! - TipRanks
Madrigal Pharmaceuticals’ senior VP sells $4.8 million in stock By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals’ senior VP sells $4.8 million in stock - Investing.com India
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Holdings Reduced by Principal Financial Group Inc. - Defense World
Boston Pharma Plays Catch Up To Akero, 89bio In MASH - insights.citeline.com
Madrigal Pharmaceuticals CFO Mardi sells $637,247 in stock - Investing.com India
Madrigal Pharmaceuticals exec sells $418,488 in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals exec sells $418,488 in stock - Investing.com
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):